Immunomedics
Industry | Parent Gilead Sciences | |
---|---|---|
Website | www |
Immunomedics was a
antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]
History
Immunomedics was founded in July 1982 by David M. Goldenberg.[2]
Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]
In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. [5]
Products
- Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.[citation needed]
- Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.[citation needed]
- Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.[citation needed]
- IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.[citation needed]
- IMMU-114 is an anti-HLA-DR for hematological cancers.[8]
References
- ^ a b "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.
- TheStreet.com.
- ^ Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.
- ^ "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.
- ^ "Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters". 8 March 2022.
- ^ "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020.
- TheStreet.com.
- S2CID 8988947.